Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England-Reference-Cited by-同舟云学术

Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England

Published:2024-08-07 Issue: Volume: Page:
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Fox Christopher P.¹^ORCID,Townsend William²^ORCID,Gribben John G.³,Menne Tobias⁴^ORCID,Kalakonda Nagesh⁵,Williams Paula⁶,Toron Farah⁶,Tyas Emma⁷,Cooper Miranda⁷,Rickards Joshua⁷,Radford John⁸

Affiliation:

1. School of Medicine University of Nottingham Nottingham UK

2. University College London Hospitals NHS Foundation Trust London UK

3. Barts Cancer Institute Barts Health NHS Trust London UK

4. Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK

5. Molecular & Clinical Cancer Medicine University of Liverpool Liverpool UK

6. Bristol Myers Squibb Uxbridge UK

7. Lumanity Farnham UK

8. Manchester Academic Health Science Centre The Christie NHS Foundation Trust and University of Manchester Manchester UK

Abstract

AbstractAutologous stem‐cell transplantation (ASCT) is standard therapy for relapsed/refractory large B‐cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression‐free survival (PFS) and event‐free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.970

Reference14 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2. NICE.Non‐Hodgkin's lymphoma: diagnosis and management.2016. Accessed: 05/12/23.https://www.nice.org.uk/guidance/ng52

3. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

4. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

5. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?